Skip to main content
. Author manuscript; available in PMC: 2012 Dec 10.
Published in final edited form as: Vaccine. 2008 Dec 25;27(7):987–994. doi: 10.1016/j.vaccine.2008.12.002

Table 2.

Specific release of IFN-γ by CEA-specific T cells stimulated by DCs treated with CEA peptide, CD40L, and/or control yeast.

DCs Treatment CEA-6D peptide CEA-specific T cells IFN-γ
− − − + <15.6
+ − − − <15.6
+ − − + <15.6
+ − + + 47.4
+ CD40L − − <15.6
+ CD40L − + <15.6
+ CD40L + + 535.5
+ Control yeast − − <15.6
+ Control yeast − + <15.6
+ Control yeast + + 534.3

DCs were generated from PBMCs of healthy HLA-A2+ donors and treated at a DC:yeast ratio of 1:5.T cell:APC ratio was 10:1. DCs treated with CD40L (1 μg/ml) were cultured for 24 h, then pulsed with CEA-6D peptide at 10 μg/ml. DCs treated with control yeast were cultured for 48 h, then pulsed with CEA-6D peptide at 10 μg/ml. CEA-specific V8T cells were stimulated with peptide-pulsed or unpulsed DCs. Supernatants were harvested after 24 h and screened for production of IFN-γ by ELISA. Results are expressed in pg/ml.